IFNA1 and systemic lupus erythematosus: In this short-term study, using both MRL/lpr and NZB/W F1 lupus-prone mouse models, we show that captopril, a BBB-crossing, centrally acting ACEi, effectively reduces IFN responses, peripheral and neuroinflammation and autoantibody levels, when administered at an early disease stage.